What question did this study set out to answer?

To determine the impact of TP53 mutations and prior cytotoxic exposure on survival in CCUS patients.

December 8, 2025BloodOpen Access

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

View Full Paper

Ask AI

Bookmark

Authors

YJYazan Khair Eldien Jabban WHWilliam J. Hogan MPMrinal M. Patnaik

Discussion

Member takes

Overview

Observational study reveals cytotoxic exposure and cytopenia worsen survival in TP53-mutated myeloid neoplasms, suggesting risk stratification should focus on clinical context.

Key Points

To determine the impact of TP53 mutations and prior cytotoxic exposure on survival in CCUS patients.
Evaluated adult patients with CCUS at Mayo Clinic and South Australian MDS Registry.
Defined CCUS and MDS based on WHO classification excluding MDS-defining cytogenetics.
Conducted next-generation sequencing for mutations and assessed survival using Kaplan-Meier and Cox regression.
15.6% of CCUS cases harbored TP53 mutations, which are linked to poorer survival outcomes.
Prior cytotoxic exposure and cytopenia, particularly anemia, were significant factors impacting survival.
TP53 mutations did not independently predict inferior survival outcomes or leukemia transformation in CCUS.

Cite This Study

Jabban et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d893 https://doi.org/10.1182/blood-2025-5643

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

View Full Paper

Ask AI

Bookmark

Authors

YJYazan Khair Eldien Jabban WHWilliam J. Hogan MPMrinal M. Patnaik

Discussion

Member takes

Overview

Observational study reveals cytotoxic exposure and cytopenia worsen survival in TP53-mutated myeloid neoplasms, suggesting risk stratification should focus on clinical context.

Key Points

To determine the impact of TP53 mutations and prior cytotoxic exposure on survival in CCUS patients.
Evaluated adult patients with CCUS at Mayo Clinic and South Australian MDS Registry.
Defined CCUS and MDS based on WHO classification excluding MDS-defining cytogenetics.
Conducted next-generation sequencing for mutations and assessed survival using Kaplan-Meier and Cox regression.
15.6% of CCUS cases harbored TP53 mutations, which are linked to poorer survival outcomes.
Prior cytotoxic exposure and cytopenia, particularly anemia, were significant factors impacting survival.
TP53 mutations did not independently predict inferior survival outcomes or leukemia transformation in CCUS.

Cite This Study

Jabban et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d893 https://doi.org/10.1182/blood-2025-5643

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark